Published in @bjsurgery.bsky.social, unique nationwide 🇳🇱 data @dpcgofficial.bsky.social on #NCCN resectability staging of #PancreaticCancer at diagnosis:
🧷 23% PRPC
🧷 8% BRPC
🧷 11% LAPC
🧷 58% M1
… including stratification for tumour location.

👉 academic.oup.com/bjs/article/...

Published in #BJC, our 🌎 study with 935 localized #pancreaticancer patients after resection, comparing preoperative FFX vs GnP:

📎FFX vs GnP not associated with OS (p=0.17)
📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology
🚨Pragmatic RCT #chemosensitivitymarkers🔍

👉 www.nature.com/articles/s41...

Published in @thelancet.bsky.social, our review on #PancreaticCancer
📎Epidemiology🌎
📎Pathogenesis🔬
📎Risk factors & surveillance🕵️
📎Diagnostics🩺
📎Treatment💊
📎Future directions🔍
… by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.

Published in #hpbjournal, 🌎 survey on surgical management of pancreatic neck/body cancer with venous involvement:

📝222 surgeons, 49 countries, 6 continents

📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement

⚠️ Need for research 🔍

@eahpba.bsky.social @ihpba.bsky.social

In #BMC Cancer, #PREOPANC4 protocol to improve #LAPC care in 🇳🇱 @dpcgofficial.bsky.social with help of 4 international experts🇩🇪🇺🇸:

📎Multidisciplinary & surgical training program
📎Structured induction therapy, response evaluation & selection for surgery
📎National expertpanel
📎Patient-centered care

In JAMA Oncology our 🌎 @eahpba.bsky.social study on adjuvant chemo (AT) in 742 resected localized #PDAC patients following NAT #FFX (40 centers):

📌OS ⬆️ by AT;
… only with multi-agent AT ⚠️

📌Possibly less effect of AT if >=8c NAT FFX, RECIST response, ypN0 & head tumor 📣

📯RCT🟰🔑

PVR 1-2 vs 3-4 during pancreatoduodenectomy for resectable #PDAC with venous involvement?

In Annals of Surgery, our observational study with 357 patients from 🇸🇪🇯🇵🇳🇱🇺🇸:

📌PVR type NOT associated with OS, locoregional recurrence & major morbidity

➡️ surgeon’s personal preference